S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
RCKT · Rocket Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Rocket Pharmaceuticals Inc (RCKT)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$2.19
-0.15
(-6.20%)
● At close: October 21 at 4:00:00 PM EDT
$2.20
+0.00
(+0.00%)
Overnight:
11:26:59 PM EDT
DAY'S RANGE
$2.19
$2.17
$2.38
52-WEEK RANGE
$2.19
$2.17
$5.45
What's happening
- RCKT is down 6.20% today, trading at $2.19. — Live quote
- It's trading within 3% of its 52-week low ($2.17). (Finnhub fundamentals)
- Volume today (115,216) is well below its 3-month average of 2,066,370. (Finnhub fundamentals)
- Reports earnings on 2026-11-05 (after market close), 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.48 actual vs. $0.25 estimated (-294.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 8
Hold 6
Sell 2
Strong sell 0
Aggregate ratings for 2026-10-01 (20 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RCKT
-33.33%
vs S&P 500
-46.11%
1-YEAR RETURN
RCKT
-41.50%
vs S&P 500
-56.06%
6-MONTH RETURN
RCKT
-40.00%
3-MONTH RETURN
RCKT
-31.18%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.48
Est. $0.25
MISS -294.6%
2026-04-26 (Q1 2026)
$-0.42
Est. $-0.42
MISS -1.2%
2026-01-26 (Q4 2025)
$-0.38
Est. $-0.46
BEAT +17.8%
2025-10-26 (Q3 2025)
$-0.45
Est. $-0.52
BEAT +12.6%
Valuation Measures & Ratios
Enterprise Value4$44.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book71.01
EV4 / Revenue—
EV4 / EBITDA4.90
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-5.76%
Return on Assets (ROA9)-4.90%
Avg Volume (3M)2,066,370
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $391.3M | $405.7M | $365.2M | $271.8M | $728.3M |
| P/E | -8.97 | -1.78 | -1.48 | -1.02 | -2.80 |
| Price/Book | 1.06 | 1.70 | 1.16 | 0.77 | 1.77 |
| EV/EBITDA | -0.79 | -1.57 | -1.17 | — | — |
| ROE | -11.83% | -95.86% | -78.84% | -75.27% | -63.03% |
| ROA | -10.31% | -79.95% | -67.20% | -63.33% | -55.14% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short15,049,780
Change from Prior Settlement+1.36%
% of Float—
Days to Cover (Short Ratio)6.94
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -41.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RCKT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$46.9M | -$48.5M | -$52.2M | -$71.1M | -$64.4M | -$69.4M | -$73.7M | -$67.4M |
| Net income | $123.2M | -$47.6M | -$50.3M | -$68.9M | -$61.3M | -$66.7M | -$69.6M | -$62.1M |
| EPS (diluted) | $1.08 | $-0.42 | $-0.45 | $-0.62 | $-0.56 | $-0.71 | $-0.74 | $-0.66 |
| EPS (basic) | $1.09 | $-0.42 | $-0.45 | $-0.62 | $-0.56 | $-0.71 | $-0.74 | $-0.66 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $423.1M | $285.4M | $330.4M | $368.0M | $421.0M | $471.1M | $527.7M | $393.7M |
| Total liabilities | $54.3M | $47.4M | $53.2M | $54.4M | $66.8M | $58.9M | $64.5M | $63.9M |
| Stockholders' equity | $368.8M | $238.0M | $277.2M | $313.7M | $354.2M | $412.1M | $463.2M | $329.8M |
| Total current assets | $289.6M | $149.8M | $192.7M | $227.7M | $277.2M | $324.5M | $378.2M | $241.8M |
| Total current liabilities | $31.3M | $24.5M | $30.2M | $31.2M | $43.4M | $35.3M | $40.7M | $40.0M |
| Cash & equivalents | $224.5M | $49.6M | $77.6M | $75.9M | $32.8M | $49.8M | $163.6M | $65.6M |
| Marketable securities (current) | $59.2M | $94.8M | $111.4M | $146.8M | $238.7M | $268.4M | $208.7M | $170.1M |
| Marketable securities (non-current) | — | — | — | — | — | — | $0 | $0 |
| Property, plant & equipment | $25.1M | $26.7M | $28.2M | $29.8M | $32.5M | $34.6M | $36.8M | $38.5M |
| Goodwill | $39.2M | $39.2M | $39.2M | $39.2M | $39.2M | $39.2M | $39.2M | $39.2M |
| Intangible assets | $25.1M | $25.1M | $25.1M | $25.1M | $25.1M | $25.1M | $25.1M | $25.1M |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | — | — | — | — | — | — | — | — |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M |
| Common stock & paid-in capital | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $911.0K |
| Retained earnings | -$1.37B | -$1.49B | -$1.44B | -$1.40B | -$1.35B | -$1.28B | -$1.22B | -$1.16B |
| Accumulated other comprehensive income (loss) | -$106.0K | -$112.0K | -$31.0K | -$9.0K | -$107.0K | -$27.0K | $66.0K | $213.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.6M | -$45.4M | -$34.8M | -$50.4M | -$49.0M | -$55.8M | -$46.9M | -$52.1M |
| Investing cash flow | $214.4M | $17.4M | $36.4M | $93.6M | $31.8M | -$58.0M | -$37.9M | $78.9M |
| Financing cash flow | $150.0K | -$1.0K | $0 | -$67.0K | $215.0K | $0 | $182.8M | $176.0K |
| Free cash flow | -$39.6M | -$45.5M | -$34.9M | -$50.4M | -$49.0M | -$56.2M | -$47.3M | -$53.7M |
| Capital expenditures | $8.0K | $93.0K | $80.0K | -$54.0K | $50.0K | $364.0K | $309.0K | $1.6M |
| Depreciation & amortization | $1.6M | $1.6M | $6.4M | $2.7M | $2.0M | $2.5M | $5.5M | $1.9M |
| Share-based compensation | $7.4M | $8.5M | $6.1M | $9.8M | $10.9M | $10.3M | $11.1M | $11.2M |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $14.8M | $48.7M | $54.5M | $29.4M | $52.7M | $139.9M | $124.0M | $19.3M |
| Share repurchases | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$231.7M | -$273.2M | -$259.7M | -$224.3M | -$167.2M |
| Net income | -$223.1M | -$258.7M | -$245.6M | -$221.9M | -$169.1M |
| EPS (diluted) | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 |
| EPS (basic) | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M |
| Stockholders' equity | $277.2M | $463.2M | $492.6M | $489.7M | $454.7M |
| Total current assets | $192.7M | $378.2M | $378.2M | $364.1M | $392.1M |
| Total current liabilities | $30.2M | $40.7M | $48.5M | $39.2M | $22.2M |
| Cash & equivalents | $77.6M | $163.6M | $55.9M | $140.5M | $232.7M |
| Marketable securities (current) | $111.4M | $208.7M | $317.3M | $215.9M | $156.0M |
| Marketable securities (non-current) | — | $0 | $34.3M | $43.3M | $0 |
| Property, plant & equipment | $28.2M | $36.8M | $39.2M | $29.0M | $22.3M |
| Goodwill | $39.2M | $39.2M | $39.2M | $39.2M | $30.8M |
| Intangible assets | $25.1M | $25.1M | $25.1M | $25.7M | $0 |
| Other non-current assets | — | — | — | — | — |
| Accounts payable | — | — | — | — | — |
| Accrued liabilities | — | — | — | — | — |
| Other non-current liabilities | $1.1M | $1.1M | $2.9M | $2.6M | $80.0K |
| Common stock & paid-in capital | $1.1M | $1.1M | $903.0K | $791.0K | $645.0K |
| Retained earnings | -$1.44B | -$1.22B | -$959.4M | -$713.8M | -$491.9M |
| Accumulated other comprehensive income (loss) | -$31.0K | $66.0K | $319.0K | -$357.0K | -$161.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$190.0M | -$209.7M | -$194.9M | -$178.1M | -$121.2M |
| Investing cash flow | $103.8M | $131.7M | -$98.1M | -$69.3M | $18.9M |
| Financing cash flow | $148.0K | $185.7M | $208.4M | $155.3M | $37.7M |
| Free cash flow | -$190.5M | -$215.6M | -$211.4M | -$186.5M | -$128.8M |
| Capital expenditures | $440.0K | $5.9M | $16.4M | $8.4M | $7.6M |
| Depreciation & amortization | $8.9M | $7.2M | $4.9M | $3.9M | $3.2M |
| Share-based compensation | $37.1M | $43.9M | $39.4M | $31.0M | $29.2M |
| Change in accounts payable | — | — | — | — | — |
| Purchases of investments | $276.6M | $245.9M | $390.9M | $376.3M | $245.9M |
| Share repurchases | — | — | — | — | $0 |
| Tax withholding on stock comp | — | — | — | $0 | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RCKT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:57 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-06 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-11 | View on SEC.gov → |
| 2026-09-15 | 8-K | 2026-09-15 | View on SEC.gov → |
| 2026-08-27 | 8-K | 2026-08-21 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-11 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-11 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about RCKT (Rocket Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Rocket Pharmaceuticals (RCKT) Rises 4.46% to $2.34 as Shares Press Toward Resistance - Fear Greed Extreme
https://www.dars.gov.et/ · 2026-10-21 -
Rocket Pharmaceuticals schedules November 5 results for Rocket Pharmaceuticals stock
AD HOC NEWS · 2026-10-20 -
Rocket Pharmaceuticals stock fell 7.63 percent to USD 2.18, 0.46 percent above yearly low - ad-hoc-news.de
ad-hoc-news.de · 2026-10-17 -
Goldman Sachs raises target to USD 4.00 for Rocket Pharmaceuticals stock
AD HOC NEWS · 2026-10-15 -
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
Yahoo · 2026-10-15 -
Rocket Pharmaceuticals will join a healthcare panel Tuesday and meet with investors.
Stock Titan · 2026-10-15 -
Rocket Pharmaceuticals Inc (RCKT) Stock Price Target & Forecast
TradingKey · 2026-10-15 -
FDA unveils rare disease initiative to enhance therapy development
Seeking Alpha · 2026-10-14
No headlines in this category right now — try “All”.